Home > Insider Trading > Filing (0001593968-20-001498)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
887359	Vericel Corp	VCEL	Biological Products, (No Disgnostic Substances) (2836)	943096597

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1778858	Michael Halpin	C/O Vericel Corporation 64 Sidney Street Cambridge MA 02139	Chief Operating Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-06-16	2,890	$2.65	5,624	No	4	M	Direct
Common Stock	Disposition	2020-06-16	2,890	$15.00	2,734	No	4	S	Direct
Common Stock	Disposition	2020-06-16	1,112	$15.00	1,622	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Vcel	Stock Option (right to buy)	Disposition	2020-06-16	2,890	$0.00	2,890	$2.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
77,063		2027-04-10	No	4	M	Direct

Footnotes

These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020.
Each restricted stock unit represents the right to receive, at settlement, one common share of stock.
These disposed shares were from an award that was granted on February 6, 2019. 1,875 restricted stock units subject to the award vested on February 6, 2020, and 1,875 restricted stock units are scheduled to vest on February 6, 2021, February 6, 2022, and February 6, 2023, contingent on continued service to the company.
These options, representing the right to purchase 135,000 shares, became exercisable on April 10, 2018, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.